<DOC>
	<DOCNO>NCT01897727</DOCNO>
	<brief_summary>Hypertension affect estimate 60-70 million Americans , predispose potentially life threaten cardiovascular complication . Resistant hypertension , define uncontrolled blood pressure 3 different antihypertensive agent , common , affect 15-20 % entire hypertensive population estimate 12-14 million Americans . Although associated obesity , increase age , black race , chronic kidney disease , mechanism treatment resistance remain obscure . The investigator ' laboratory identify primary aldosteronism ( PA ) common cause treatment resistance prevalence 20 % among subject resistant hypertension . This clinically important recognition PA lead effective treatment use aldosterone blocker . Obstructive sleep apnea ( OSA ) strongly associate predicts development hypertension demonstrate landmark cohort study include Sleep Heart Health Study Wisconsin Sleep Cohort Study . The investigator ' laboratory confirm OSA extremely common subject resistant hypertension , prevalence approximately 85 % . Recognizing PA OSA exceptionally common subject resistant hypertension , investigator hypothesize 2 may causally relate . In test hypothesis , investigator recently report plasma aldosterone level positively correlate OSA severity subject resistant hypertension normotensive control subject . This observation suggest important mechanistic interaction untreated OSA aldosterone excess subject resistant hypertension . While investigator ' original hypothesis OSA stimulate aldosterone release , investigator recognize opposite may also true ; , aldosterone excess subject resistant hypertension worsens OSA . Distinguishing two possibility potentially far-reaching clinical implication . If former hypothesis true , effective treatment OSA would expect suppress aldosterone release subject resistant hypertension , thereby reverse underlie cause treatment resistance . If latter hypothesis true , use mineralocorticoid receptor antagonist would expect reduce OSA severity subject resistant hypertension , thereby enhance treatment OSA . Either scenario would represent new treatment approach highly prevalent serious medical problem .</brief_summary>
	<brief_title>Etiology Sleep Apnea-related Hyperaldosteronism - BP Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Hyperaldosteronism</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Resistant hypertension define office BP uncontrolled 3 antihypertensive medication Moderatesevere OSA define AHI â‰¥15 events/hr Selfreported adherence &gt; 80 % prescribed antihypertensive medication . Ongoing use potassium spar diuretic History congestive heart failure ( ejection fraction &lt; 40 % ) Chronic kidney disease ( creatinine clearance &lt; 60 ml/min ) History cardiovascular disease ( stroke , TIA , myocardial infarction , revascularization procedure ) Known suspect history secondary cause hypertension primary aldosteronism Severe nocturnal hypoxemia ( O2 desaturation nadir &lt; 60 % ) White coat hypertension define office BP &gt; 140/90 mm Hg ambulatory daytime BP &lt; 135/85 mm Hg Central sleep apnea ( defined 5 % apneas central apnea ) and/or presence CheyneStokes breathing Subjects work shift work know circadian rhythm disorder sleepwake schedule alter Excessive daytime sleepiness indicate Epworth score &gt; 10 Pregnant Women</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>sleep apnea</keyword>
	<keyword>hypertension</keyword>
	<keyword>aldosterone</keyword>
	<keyword>hyperaldosteronism</keyword>
	<keyword>spironolactone</keyword>
	<keyword>blood pressure</keyword>
	<keyword>resistant</keyword>
</DOC>